Corrections, Citations, New Data

Corrections and citations

This desk welcomes notes on the record itself: a study summarized loosely, a trial that has since posted results, a regulatory status that has moved, or a peer-reviewed paper on ipamorelin, CJC-1295 or tesamorelin that belongs on the references page. A correction that makes a figure more accurate or more current is the most useful message that arrives here, and each one is checked against its source before anything is changed.

The notes easiest to act on name three things: which page, the exact passage in question, and the supporting reference - a digital object identifier or a PubMed identifier wherever one exists. In that form, a proposed change can be verified rather than merely considered.

Editorial mailbox: editors@peptideprosolutions.com

Outside this desk's remit

So that no message goes unanswered for the wrong reason, several requests fall outside what a literature desk can do. Because this site reports published research rather than practicing medicine or selling anything, it cannot:

• Advise on, endorse or evaluate human use of any compound covered here.
• Name a dose, a schedule or a route for any individual.
• Judge whether a finding from a cited trial applies to a particular person.
• Source, supply or help locate any compound from any seller.
• Provide a route to prescription medicines outside a licensed prescriber-patient relationship.
• Advise athletes subject to anti-doping rules, since all three compounds covered here are prohibited in sport at all times under category S2.

Tesamorelin is an approved prescription medicine in one narrow indication; ipamorelin and CJC-1295 are not approved for human use anywhere. Anyone seeking clinical guidance should take it to a licensed clinician in their own jurisdiction. Replies are not guaranteed and can be slow; the mailbox is read in batches.